(redirected from Cayston)
Also found in: Thesaurus, Medical.


A synthetic antibiotic, C13H17N5O8S2, that acts against a wide spectrum of gram-negative bacteria.

[Variant of azthreonam : az(o)- + threon(ine) (used as a template for the antibiotic's chirality) + (beta-lact)am.]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.aztreonam - an antibiotic (trade name Azactam) used against severe infections; has minimal side effects
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
References in periodicals archive ?
Gilead also announced today the establishment of a program designed to minimize barriers to access for Cayston for uninsured, privately insured and government-insured people with cystic fibrosis.
Food and Drug Administration approved an important new inhaled antibiotic called Cayston (aztreonam for inhalation solution) today for the treatment of cystic fibrosis.
Applications for marketing approval of Cayston are also pending in Australia, Switzerland and Turkey.
Cayston will be made available in certain countries of the European Union, subject to the requirements of national authorities, beginning in early 2010.
23 /PRNewswire/ -- Altera, which uses eFlow Technology, was cleared to market today by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg.
Cayston was approved and the Altera Nebulizer System was cleared by the U.
In February, Gilead announced that the FDA granted marketing approval for Cayston as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with P.
In addition, allergic reaction with facial rash, facial swelling and throat tightness was reported with Cayston in clinical trials.
While at Gilead, he served as Senior Vice President and Head of Respiratory Therapeutics where he successfully led the approval of Cayston (aztreonam) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
In June, Gilead announced that its head-to-head Phase III clinical trial of Cayston versus tobramycin inhalation solution in cystic fibrosis patients with P.
Gilead Receives US FDA Approval for Marketing Cayston in the US II-37